Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition for treating neurasthenia or somatic form disorders

A somatoform disorder and composition technology, applied in the field of pharmacy, can solve the problems of inaccurate curative effect, reduce the curative effect of various emotional symptoms, etc., and achieve the effects of stable and long-lasting effect, fast onset of effect, and reduction of incidence and intensity.

Active Publication Date: 2010-12-08
SHENZHEN AUSA PHARM CO LTD +2
View PDF20 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The reason for this is mainly because SSRI drugs only selectively act on the 5-HT system, but do not affect the NE system, which also plays an important role in the occurrence and development of depression, anxiety, irritability and other emotional abnormalities. effect on affective symptoms
At the same time, the efficacy of such drugs on neurotic disorders such as neurasthenia and neurotic depression with a relatively long course is even more uncertain.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating neurasthenia or somatic form disorders
  • Medicinal composition for treating neurasthenia or somatic form disorders
  • Medicinal composition for treating neurasthenia or somatic form disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] Example 1 Prepare reboxetine-sertraline compound tablets (1000 tablets) containing 1 mg reboxetine and 12.5 mg sertraline.

[0075] Formula: Reboxetine 1g

[0076] Sertraline 12.5g

[0077] Lactose 50g

[0078] Microcrystalline Cellulose 50g

[0079] Starch 10g

[0080] Sodium carboxymethyl starch 30g

[0081] Magnesium Stearate 1g

[0082] Preparation method: pulverize 1g of reboxetine, 12.5g of sertraline, 50g of lactose, 50g of crystal cellulose and 10g of starch, mix them uniformly, make a soft material with 10% povidone ethanol solution, granulate, dry, For granulation, the granules with a water content of about 3% are uniformly mixed with magnesium stearate, and compressed into tablets with a tablet machine. Each of the prepared compound tablets contains 1 mg of reboxetine and 12.5 mg of sertraline, with a mass ratio of 1:12.5.

Embodiment 2

[0083] Example 2 Prepare reboxetine-sertraline compound tablets (1000 tablets) containing 32 mg reboxetine and 150 mg sertraline.

[0084] Formula: Reboxetine 32g

[0085] Sertraline 150g

[0086] Lactose 50g

[0087] Microcrystalline Cellulose 50g

[0088] Starch 10g

[0089] Sodium carboxymethyl starch 30g

[0090] Magnesium Stearate 1g

[0091] Preparation method: as in the compound method of Example 1, each tablet contains 32 mg of reboxetine and 150 mg of sertraline in the prepared compound tablet, and its mass ratio is 16:75.

Embodiment 3

[0092] Example 3 Reboxetine-citalopram compound tablets (1000 tablets) containing 4 mg reboxetine and 20 mg citalopram were prepared.

[0093] Formula: Reboxetine 4g

[0094] Citalopram 20g

[0095] Lactose 50g

[0096] Microcrystalline Cellulose 50g

[0097] Starch 10g

[0098] Sodium carboxymethyl starch 30g

[0099] Magnesium Stearate 1g

[0100] Preparation method: As in the preparation method of Example 1, each of the prepared compound tablets contains 4 mg of reboxetine and 20 mg of citalopram, and the mass ratio is 1:5.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for curing and preventing neurosism or somatic formal disturbance and its medicine composition. Said invention belongs to the field of pharmacy. Said invention provides a medicine composition containing norepinephrine reuptake inhibitor with medicinal dose or its medicinal salt and selective 5-hydroxytryptamine reuptake inhibitor with medicinal dose or its medicinal salt for preventing and curing neurosism or somatic formal disturbance. The norepinephrine reuptake inhibitor is selected from reboxetine, tomoxetine, amfebutamone, nortriptyline, norimipramine, maprotiline and protiline, and the selective 5-hydroxytryptamine reuptake inhibitor is selected from sertraline, citalopram, s-citalopram, fluoroxeline, paroxetine and fluvoxamine.

Description

technical field [0001] The present invention relates to a method and a pharmaceutical composition for treating neurasthenia or somatoform disorder, wherein the active ingredients contain a norepinephrine reuptake inhibitor or a pharmaceutically acceptable salt thereof and a serotonin reuptake inhibitor or a pharmaceutically acceptable salt thereof . The present invention belongs to the field of pharmacy. Background technique [0002] Neurasthenia (neurasthenia) is a common mental disorder. Chapter 5 of the Tenth Edition of the International Classification of Diseases in 1992 (ICD-10) has descriptions and diagnostic criteria for neurasthenia (F48.0). The definition of neurasthenia in the third edition of the Chinese Classification of Mental Disorders (CCMD-3) revised by the Psychiatric Branch of the Chinese Medical Association in 2003 is as follows: [0003] Neurasthenia (CCMD-3 code: 43.5; ICD-10 code: F48.0): Refers to a neurosis characterized by weakened brain and body ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/5375A61K31/137A61K9/20A61K9/16A61K9/48A61K9/52A61K9/08A61K9/10A61P25/20A61P25/00
Inventor 刘平于多龙海珍李劲彤李华王玉戴成祥陈光亮邢厚恂徐希平
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com